HIV virus, Credit: C. Goldsmith Content Providers: CDC/ C. Goldsmith, P. Feorino, E. L. Palmer, W. R. McManus
Donald Trump’s administration has quietly suspended a study that was conducting research into a possible HIV cure.
As reported by Science magazine, in September the Department of Health and Human Services (HHS) barred the National Institute of Health (NIH) from accessing fetal tissue for research.
The blockade came without any public announcement, and was reportedly part of a federal review of all research conducted by the government that utilized fetal tissue. The tissue itself is legal to use, but is acquired from elective abortions — a practice strongly opposed by anti-abortion activists, Trump administration officials, and Trump himself.
Fetal tissue was being utilized by researchers working for NIH’s National Institute of Allergy and Infectious Diseases (NIAID), as part of a study into how HIV takes hold in the body.
NIAID’s Rocky Mountain Laboratories (RML) in Montana was using the tissue to create mice with immune systems that behave like a human’s, which plays a key role in testing and researching antibodies and drugs to treat and combat HIV. RML used the mice to investigate the potential of a new antibody to prevent HIV from creating “reservoirs” of the virus in the body.
RML acquired its tissue from a laboratory in California for “several years,” according to Science, but in September the lab was informed that no more tissue could be ordered.
“[HHS] has directed me to discontinue procuring fetal tissue,” an RML researcher wrote in an email obtained by Science. “I think that they are the only provider of fetal tissue for scientists in the nation who don’t have direct access to aborted fetal tissue. This effectively stops all of our research to discover a cure for HIV.”
An NIH spokesperson confirmed that the agency had told scientists to “pause procurements of fetal tissue,” pending a review by HHS.
An NIAID spokesperson said: “We have instituted a pause of further procurements pending the audit/review that HHS is undertaking.”
Warner Greene, an HIV researcher and director of the Gladstone Center for HIV Cure Research in San Franciscio, Calif. — which was collaborating with the NIH — said that news of the block on fetal tissue was a “bombshell.”
“We were all poised to go and then the bombshell was dropped,” Greene told Science. “The decision completely knocked our collaboration off the rails. We were devastated.”
Thomas Packard, a postdoctoral student working under Greene, called it a “travesty for the outlook for HIV research.”
“Mice made with human fetal tissue are critical to moving from discoveries in the lab to clinical treatments,” he told Science. “Blocking this significantly hurts our chances of finding an HIV cure.”
In a statement to Gay Star News, a spokesperson for HHS said that there was a pause on fetal tissue procurement, pending an audit, but did not state whether it would be permanently blocked from being acquired by federal researchers.
“In September, HHS issued a statement announcing an audit would be conducted of all acquisitions involving human fetal tissue to ensure conformity with procurement and human fetal tissue research laws and regulations,” the spokesperson said. “In addition, HHS has initiated a comprehensive review of all research involving fetal tissue to ensure consistency with statutes and regulations governing such research, and to ensure the adequacy of procedures and oversight of this research in light of the serious considerations involved.”
It’s not the first time that Trump’s administration has crossed paths with HIV research and efforts to end America’s HIV/AIDS epidemic.
“As advocates for people living with HIV, we have dedicated our lives to combating this disease and no longer feel we can do so effectively within the confines of an advisory body to a president who simply does not care,” the six resignees wrote in an open letter.
Trump was also heavily criticized for his administration’s HIV strategy after releasing a statement recognizing National HIV Testing Day in 2017 that failed to even mention LGBTQ people.
Please Support Metro Weekly
As a free LGBTQ publication, Metro Weekly relies on advertising in order to bring you unique, high quality journalism, both online and in our weekly edition. The ongoing coronavirus pandemic has forced many of our incredible advertisers to temporarily close their doors to protect staff and customers, and so we’re asking you, our readers, to help support Metro Weekly during this trying period. We appreciate anything you can do, and please keep reading us on the website and our new Digital Edition, released every Thursday and available for online reading or download.
Rhuaridh Marr is Metro Weekly's managing editor. He can be reached at firstname.lastname@example.org.
Strictly Necessary Cookies
Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.
If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.